Hemophagocytic Lymphohistiocytosis Mimics in Sepsis: Navigating the Diagnostic Minefield in Critical Care

Dr Neeraj Manikath , claude.ai

Abstract

Background: Hemophagocytic lymphohistiocytosis (HLH) presents a diagnostic challenge in critically ill patients, particularly when occurring in the context of sepsis. The overlapping clinical presentations can lead to delayed diagnosis and inappropriate treatment, with significant morbidity and mortality implications.

Objective: To provide critical care physicians with a systematic approach to differentiating HLH from sepsis mimics, emphasizing diagnostic red flags and therapeutic decision points.

Methods: Comprehensive review of literature from 2015-2024, focusing on adult HLH in critical care settings, diagnostic biomarkers, and treatment algorithms.

Results: HLH mimics in sepsis include cytokine storm syndromes, severe bacterial sepsis with macrophage activation, drug-induced hypersensitivity syndromes, and malignancy-associated inflammatory responses. Key diagnostic discriminators include ferritin patterns, cytokine profiles, and hemophagocytic activity on bone marrow examination.

Conclusions: Early recognition of HLH requires high clinical suspicion, systematic application of diagnostic criteria, and understanding of when to escalate from antimicrobial therapy to immunosuppressive treatment.

Keywords: Hemophagocytic lymphohistiocytosis, sepsis, cytokine storm, ferritin, critical care

Introduction

Hemophagocytic lymphohistiocytosis (HLH) represents one of the most challenging diagnostic entities in critical care medicine. Originally described as a pediatric condition, adult HLH is increasingly recognized as a life-threatening hyperinflammatory syndrome that can masquerade as refractory sepsis¹. The syndrome is characterized by dysregulated immune activation, leading to excessive cytokine production and tissue damage that can rapidly progress to multi-organ failure².

The diagnostic complexity intensifies in the intensive care unit (ICU), where sepsis and HLH share remarkably similar clinical presentations. Both conditions present with fever, cytopenias, coagulopathy, and organ dysfunction. However, the therapeutic approaches are diametrically opposed: sepsis requires aggressive antimicrobial therapy and supportive care, while HLH demands immunosuppression³. This therapeutic paradox makes early and accurate diagnosis crucial for patient survival.

Recent epidemiological studies suggest that adult HLH may be significantly underdiagnosed in critical care settings, with mortality rates approaching 50-60% when treatment is delayed⁴. The emergence of COVID-19 and associated cytokine storms has further highlighted the importance of recognizing hyperinflammatory syndromes in critically ill patients⁵.

Pathophysiology: Understanding the Immune Dysregulation

Primary vs Secondary HLH

Primary HLH results from genetic defects in cytotoxic lymphocyte function, primarily affecting perforin, granzyme, and related pathways. While traditionally considered a pediatric disease, adult presentations with late-onset genetic mutations are increasingly recognized⁶.

Secondary HLH accounts for the majority of adult cases and can be triggered by:

Infections (viral, bacterial, fungal, parasitic)
Malignancies (particularly lymphomas)
Autoimmune diseases
Drug reactions
Transplant-related complications⁷

The Cytokine Storm Cascade

The hallmark of HLH is uncontrolled activation of macrophages and T-lymphocytes, leading to massive cytokine release. Key mediators include:

Interferon-γ (IFN-γ): Primary driver of macrophage activation
Tumor necrosis factor-α (TNF-α): Promotes tissue damage and organ dysfunction
Interleukin-6 (IL-6): Drives acute phase response and ferritin elevation
Interleukin-1β (IL-1β): Contributes to fever and systemic inflammation⁸

This cytokine milieu creates a self-perpetuating cycle of inflammation that distinguishes HLH from typical septic responses.

Clinical Presentation and Diagnostic Criteria

HLH-2004 Diagnostic Criteria

The Histiocyte Society established eight criteria for HLH diagnosis, requiring five of eight for confirmation:

Fever ≥38.5°C
Splenomegaly (clinical or radiological)
Cytopenias (affecting ≥2 cell lines):
- Hemoglobin <90 g/L
- Platelets <100 × 10⁹/L
- Neutrophils <1.0 × 10⁹/L
Hypertriglyceridemia (≥3.0 mmol/L) and/or hypofibrinogenemia (≤1.5 g/L)
Hemophagocytosis in bone marrow, spleen, or lymph nodes
Low or absent NK cell activity
Ferritin ≥500 μg/L
Elevated soluble CD25 (sIL-2R) ≥2,400 pg/mL⁹

HScore: A Probability Calculator

The HScore provides a more nuanced approach to HLH diagnosis, incorporating weighted clinical and laboratory parameters. Scores >169 suggest >90% probability of HLH, while scores 90-169 indicate intermediate probability requiring close monitoring¹⁰.

🔴 CLINICAL PEARL: Diagnostic Red Flags

The Ferritin-CRP Dissociation Sign

Ferritin >10,000 μg/L with normal or minimally elevated CRP in "refractory sepsis" should immediately trigger HLH evaluation.

This dissociation occurs because:

In sepsis: CRP rises proportionally with ferritin due to IL-6 stimulation
In HLH: Ferritin elevation is driven by different cytokine pathways (IFN-γ predominant), while CRP may remain surprisingly normal¹¹

Additional Red Flags:

Progressive cytopenias despite appropriate sepsis management
Persistent fever >7 days with negative cultures
Rapidly rising ferritin (doubling within 48-72 hours)
Triglycerides >400 mg/dL without other explanations
Fibrinogen <150 mg/dL in absence of DIC

HLH Mimics in Critical Care Settings

1. Severe Bacterial Sepsis with Macrophage Activation

Clinical Features:

Gram-negative sepsis can trigger secondary macrophage activation
Ferritin levels typically <5,000 μg/L
CRP remains elevated proportional to ferritin
Responds to appropriate antimicrobial therapy within 72 hours

Distinguishing Features:

Positive blood cultures or definitive infectious source
Procalcitonin significantly elevated (>10 ng/mL)
Improvement with source control and antibiotics¹²

2. COVID-19 Associated Cytokine Storm

Clinical Features:

Shares many HLH features: fever, cytopenias, elevated ferritin
Often associated with ARDS and coagulopathy
Ferritin levels variable (500-10,000 μg/L)

Distinguishing Features:

Respiratory predominance of symptoms
Elevated D-dimer and fibrinogen (unlike HLH)
Lymphopenia more prominent than other cytopenias
Response to corticosteroids¹³

3. Drug-Induced Hypersensitivity Syndrome (DIHS)

Clinical Features:

Fever, rash, eosinophilia, organ dysfunction
Can present weeks after drug initiation
Often mimics sepsis with multi-organ involvement

Distinguishing Features:

Temporal relationship to drug exposure
Eosinophilia (uncommon in HLH)
Skin involvement more prominent
Improvement with drug discontinuation¹⁴

4. Malignancy-Associated Inflammatory Response

Clinical Features:

Particularly seen with lymphomas and leukemias
Can present as tumor lysis syndrome
Cytopenias from bone marrow infiltration

Distinguishing Features:

Evidence of underlying malignancy
Blast cells or abnormal lymphocytes
LDH markedly elevated
Uric acid elevation¹⁵

5. Still's Disease (Adult-Onset)

Clinical Features:

Quotidian fever pattern
Salmon-colored rash
Arthritis and myalgia
Very high ferritin levels (often >4,000 μg/L)

Distinguishing Features:

Classic rash and fever pattern
Joint involvement
Negative rheumatoid factor and ANA
Glycosylated ferritin <20%¹⁶

🧠 CLINICAL PEARL: Laboratory Diagnostics

The Ferritin Trajectory

Sepsis: Ferritin rises then plateaus or falls with treatment
HLH: Ferritin continues rising despite appropriate sepsis management
Monitor ferritin every 12-24 hours in suspected cases

Advanced Laboratory Testing

Soluble CD25 (sIL-2R): >2,400 pg/mL highly suggestive of HLH
NK cell activity: Requires specialized flow cytometry
Triglycerides: >400 mg/dL supports HLH diagnosis
Fibrinogen: Low levels (<150 mg/dL) distinguish from sepsis
LDH: Often markedly elevated (>1,000 U/L)¹⁷

Bone Marrow Examination: When and How

Indications for Bone Marrow Biopsy:

HScore >90 or clinical suspicion high
Unexplained cytopenias with hyperferritinemia
Before initiating immunosuppressive therapy

🔍 Technical Pearl:

Hemophagocytosis may be absent early in disease course or after treatment initiation. Absence does not exclude HLH.

Bone Marrow Findings in HLH:

Increased macrophages with hemophagocytic activity
Hypercellular marrow with trilineage dysplasia
Increased plasma cells and lymphocytes
Iron stores often increased¹⁸

⚖️ THERAPEUTIC CROSSROADS: When to Escalate from Antibiotics to Etoposide

Decision Algorithm:

Immediate Escalation Indicators:

Ferritin >10,000 μg/L with HScore >169
Progressive multi-organ failure despite 48-72 hours appropriate sepsis management
Bone marrow confirmation of hemophagocytosis
Two or more diagnostic red flags present

Consider Escalation (48-72 hour window):

Ferritin 5,000-10,000 μg/L with HScore 90-169
Persistent fever with negative cultures after 72 hours
Progressive cytopenias despite source control
Rising triglycerides and falling fibrinogen

Continue Sepsis Management:

Positive cultures with appropriate organism sensitivity
Improving clinical parameters within 72 hours
Ferritin <5,000 μg/L with proportional CRP elevation
HScore <90

Treatment Strategies

First-Line HLH Treatment: HLH-94 Protocol

Induction Phase (8 weeks):

Etoposide: 150 mg/m² IV twice weekly
Dexamethasone: 10 mg/m² daily for 2 weeks, then taper
Intrathecal therapy if CNS involvement

Response Assessment:

Weekly monitoring of blood counts, ferritin, triglycerides
Bone marrow reassessment at 2 weeks
Consider allogeneic transplant if poor response¹⁹

Alternative and Salvage Therapies

Alemtuzumab (anti-CD52):

Reserved for refractory cases
Dose: 10-30 mg IV daily for 5 days
Monitor for opportunistic infections²⁰

JAK Inhibitors (Ruxolitinib):

Emerging therapy for HLH
Dose: 5-20 mg BID
Particularly useful in cytokine storm scenarios²¹

Anakinra (IL-1 antagonist):

Dose: 100-400 mg daily
Useful in macrophage activation syndrome
Better safety profile than traditional chemotherapy²²

⚠️ Critical Care Management Pearls:

Infection Control: Continue antimicrobial coverage during HLH treatment
Supportive Care: Aggressive management of organ dysfunction
Monitoring: Daily CBC, ferritin, LDH, triglycerides during induction
Complications: Watch for tumor lysis syndrome with treatment initiation

Prognosis and Outcomes

Prognostic Factors

Poor Prognosis Indicators:

Age >60 years
CNS involvement
Delay in diagnosis >4 weeks
Ferritin >50,000 μg/L
Underlying malignancy²³

Survival Outcomes:

Early treatment (<2 weeks): 70-80% survival
Delayed treatment (>4 weeks): 30-40% survival
ICU patients: Overall mortality 40-60%²⁴

Long-term Sequelae

Neurological complications: 20-30% of survivors
Secondary malignancies: Risk with prolonged immunosuppression
Recurrence: 10-15% risk, higher with genetic forms²⁵

💎 ADVANCED CLINICAL PEARLS & OYSTERS

Pearl 1: The "Sepsis Mimic Triad"

HLH presenting as sepsis typically shows:

Disproportionate ferritin elevation (>10× upper normal)
Persistent fever despite appropriate antibiotics >72 hours
Progressive cytopenias rather than improvement

Pearl 2: COVID-19 Era Considerations

Post-COVID HLH can occur weeks after apparent recovery

Monitor convalescent patients with persistent fatigue and cytopenias
Consider HLH in "long COVID" patients with hyperferritinemia

Oyster 1: The Fibrinogen Paradox

Low fibrinogen in HLH vs. high fibrinogen in sepsis

This distinction can be obscured by concurrent DIC
Serial measurements more reliable than single values

Oyster 2: Steroid Responsiveness

Dramatic improvement with steroids doesn't exclude HLH

Both conditions may respond to corticosteroids
HLH requires more aggressive immunosuppression for sustained response

Pearl 3: The "Ferritin Kinetics" Rule

Rate of ferritin rise predicts HLH likelihood:

>50% increase per day: High HLH probability
<25% increase per day: Consider other diagnoses
Plateauing ferritin: Usually sepsis with treatment response

Future Directions and Research

Emerging Biomarkers

CXCL9: Early marker of macrophage activation
Neopterin: Reflects interferon-γ activity
18F-FDG PET: May detect hemophagocytic activity²⁶

Precision Medicine Approaches

Genetic testing: Identifying adult-onset primary HLH
Cytokine profiling: Personalizing immunosuppressive therapy
Biomarker-guided therapy: Using ferritin kinetics to guide treatment intensity²⁷

Clinical Trial Landscape

Combination immunosuppression: Exploring novel drug combinations
Targeted therapies: JAK inhibitors, anti-IFN-γ monoclonals
Predictive models: AI-assisted diagnostic algorithms²⁸

🎯 PRACTICAL CLINICAL ALGORITHMS

Emergency Department/ICU Admission Algorithm:

Patient with "Refractory Sepsis" ↓ Check: Ferritin, Triglycerides, Fibrinogen, LDH ↓ If Ferritin >5,000 μg/L: Calculate HScore ↓ HScore >90: Consider HLH workup ↓ Order: sCD25, NK cell activity, Bone marrow biopsy ↓ Continue sepsis management WHILE evaluating for HLH

Treatment Decision Tree:

HLH Diagnosis Confirmed ↓ Assess CNS involvement (LP if indicated) ↓ Start HLH-94 Protocol: Etoposide + Dexamethasone ↓ Monitor response at 72 hours ↓ If improving: Continue protocol If stable/worse: Consider salvage therapy

Conclusion

Hemophagocytic lymphohistiocytosis in the critical care setting represents a diagnostic and therapeutic emergency that demands high clinical suspicion and rapid decision-making. The key to successful management lies in recognizing the diagnostic red flags—particularly the ferritin-CRP dissociation in patients with "refractory sepsis"—and understanding when to escalate from antimicrobial therapy to immunosuppressive treatment.

The therapeutic crossroads between sepsis management and HLH treatment requires careful clinical judgment, with ferritin kinetics, HScore calculation, and bone marrow examination serving as crucial decision-making tools. Early recognition and treatment can dramatically improve outcomes, with survival rates exceeding 70% when therapy is initiated within two weeks of symptom onset.

As our understanding of hyperinflammatory syndromes continues to evolve, particularly in the post-COVID era, critical care physicians must maintain heightened awareness of HLH as a treatable cause of multi-organ failure. The integration of advanced biomarkers, genetic testing, and precision medicine approaches promises to further improve diagnostic accuracy and therapeutic outcomes in this challenging condition.

The diagnostic journey from sepsis to HLH requires both clinical acumen and systematic evaluation. By applying the pearls and algorithms outlined in this review, critical care teams can navigate this complex diagnostic landscape and provide life-saving treatment to patients with this devastating but treatable condition.

Key Clinical Takeaways

Ferritin >10,000 μg/L with normal CRP should trigger immediate HLH evaluation
HScore >169 indicates >90% probability of HLH and warrants treatment
Bone marrow biopsy remains the definitive diagnostic test
Early treatment (<2 weeks) dramatically improves survival
Continue infection control measures during HLH treatment

References

Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503-1516.
Bergsten E, Horne A, Aricó M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728-2738.
Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119.
Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015;90(3):220-224.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
Zhang K, Jordan MB, Marsh RA, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011;118(22):5794-5798.
Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev. 2004;3(2):69-75.
Castillo L, Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med. 2009;10(3):387-392.
Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620.
Schaer DJ, Schleiffenbaum B, Kurrer M, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol. 2005;74(1):6-10.
Knaak C, Nyvlt P, Schuster FS, et al. Hemophagocytic lymphohistiocytosis in critically ill patients. Shock. 2020;53(6):701-709.
Prilutskiy A, Kritselis M, Shevtsov A, et al. SARS-CoV-2 infection-associated hemophagocytic lymphohistiocytosis. Am J Clin Pathol. 2020;154(4):466-474.
Shimatsu A, Sugimoto T, Adachi M, et al. Drug-induced hypersensitivity syndrome associated with hemophagocytic syndrome. Arch Dermatol. 2003;139(11):1470-1474.
Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013;162(3):376-382.
Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore). 2002;81(3):194-200.
Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;50(6):1227-1235.
Gupta A, Tyrrell P, Valani R, et al. The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;51(3):402-404.
Ehl S, Astigarraga I, von Bahr Greenwood T, et al. Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH Steering Committee of the Histiocyte Society. J Allergy Clin Immunol Pract. 2018;6(5):1508-1517.
Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60(1):101-109.
Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019;6(12):e630-e637.
Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44(2):275-281.
Machowicz R, Janka G, Wiktor-Jedrzejczak W. Your critical care patient may have HLH (hemophagocytic lymphohistiocytosis). Crit Care. 2016;20(1):215.
Buyse S, Teixeira L, Galicier L, et al. Critical care management of patients with hemophagocytic lymphohistiocytosis. Intensive Care Med. 2010;36(10):1695-1702.
Horne A, Wickström R, Jordan MB, et al. How to treat involvement of the central nervous system in hemophagocytic lymphohistiocytosis? Curr Treat Options Neurol. 2017;19(1):3.
Henter JI, Samuelsson-Horne A, Aricò M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367-2373.
Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041-4052.
La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465-2477.

Wednesday, July 23, 2025